French biotech startup Signadori Bio has secured a total of €11.1 million in Seed financing to accelerate the development of its next-generation immunotherapy platform targeting solid tumours.
The funding extension included participation from Taiho Ventures alongside existing investors Sofinnova Partners and Invivo Partners.
Developing A New Approach To Cancer Immunotherapy
Founded by Jean-Luc Perfettini and Nathalie Chaput, and based on research originating from Gustave Roussy, Signadori Bio is focused on developing off-the-shelf immunotherapies that engineer monocytes directly inside the human body.
The company’s technology is designed to activate the innate immune system and counter tumour-driven immunosuppression, with the goal of improving treatment responses in solid cancers.
Advertisement
Funding To Advance Lead Programme
The newly raised capital will support the advancement of Signadori Bio’s lead candidate, SiB-2101, toward candidate nomination, while also helping expand its in vivo monocyte engineering platform.
In addition, the company plans to strengthen its scientific and operational teams as it moves closer toward clinical development.
Dr. Selwyn Ho, Chief Executive Officer, said the financing marks a major step forward for the company as it continues to build on promising preclinical data.
He added that the company’s approach to engineering monocytes inside the body could enable a new generation of immunotherapies designed to be more scalable, accessible, and effective for patients with solid tumours.
About Signadori Bio
Signadori Bio is a preclinical-stage biotechnology company developing monocyte-based immunotherapies for cancer treatment. Its platform focuses on in vivo engineering of immune cells to enhance anti-tumour responses and improve outcomes in solid tumour therapies.
